Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(5;17)(q35;q21) NPM1/RARA

Written2000-03Franck Vigué
Laboratoire de Cytogenetique - Service d'Hematologie Biologique, Hopital Hotel-Dieu - 75181 Paris Cedex 04, France
Updated2017-01Adriana Zamecnikova, Soad al Bahar
Kuwait Cancer Control Center, Department of Hematology annaadria@yahoo.com

Abstract Acute promyelocytic leukemia (APL) is characterized by distinct clinical and biological features and by the reciprocal translocation t(15;17)(q22;q21) in the majority of patients. The translocation generates the fusion of the promyelocytic leukemia (PML) gene to the gene for retinoic acid receptor alpha (RARA) and these patients are responsive to differentiation treatment with all-trans retinoic acid (ATRA). Rare cases of patients with a morphological diagnosis of APL have variant chromosome translocations, which fuse RARA gene with partner genes other than PML, such as in the variant translocation t(5;17)(q35;q21) that fuses the N-terminus of nucleophosmin (NPM1) gene at 5q35 to the retinoic acid receptor alpha at 17q21.

Keywords Chromosome 5; chromosome 17; Acute myeloid leukaemia; Acute promyelocytic leukemia; RARA; NPM1

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
Atlas_Id 1081

Clinics and Pathology

Disease Acute myeloid leukemia (AML)
Phenotype / cell stem origin Acute promyelocytic leukemia (AML-M3 according to the FAB classification)
Etiology Exceptional; only 7 cases with balanced t(5;17)(q35;q12-21) translocation and the underlying NPM1/RARA fusion have been identified (5 males and 2 females, aged 2.5 to 52 years). There were 2 adult males, aged 29 and 52 years and 4 patients were pediatric cases, among them 2 were 12-year-old males and 2 were 2.5 and 9-year-old females (Table 1).
Clinics Disseminated intravascular coagulation was present at diagnosis in one case; remission obtained with chemotherapy and/or ATRA; first relapse at 7 and 5 months in 2 cases (Corey et al., 1994 ; Hummel et al., 1999). The 6-month-old boy described by Otsubo et al., presented with cutaneous mastocytosis and aleukemic leukemia cutis that regressed without any therapy within 6 months. Both adult patients also presented with myeloid sarcoma, therefore it is likely that it may occur frequently in NPM1/RARA associated APL (Nicci et., 2005; Kikuma et al.,2015).
Table 1. Reported cases with t(5;17)(q35;q12-21) and confirmed NPM1-RARA fusion.
 Sex/Age (years)KaryotypeClinics
1.F/2.546,XX,t(5;17)(q32;q12) 48,XX,t(5;17),+ 2marTherapy with ATRA while in partial remission, relapsed within 2 weeks of ATRA cessation.
2.M/1247,XY,t(5;17)(q35;q21),der(8)(p23), der(10)(q26),del(12)(q13q22),del(1)(q12q14),-16,-18,+21,+22,+mar Treated initially with chemotherapy, relapse occurred after 5 months. After therapy with ATRA remission was obtained, followed by bone marrow transplantation, but relapsed and remained refractory to further therapy.
3.F/946,XX,ins(3;5)(q26;q13q13),t(5;17)(q34;q21) Therapy with ATRA as a part of induction therapy; alive in remission at 29 months.
4.M/1246,XY,t(5;17)(q35;q21),del(12)(p13) Died of cerebral hemorrhage after 5 days of ATRA treatment.
5.M/29  46,XY,t(5;17)(q35;q21) Presented with granulocytic sarcoma; therapy with ATRA resulted in complete cytogenetic but not a molecular remission, relapsed at 22 months; treated with one course of arsenic trioxide.
6.M/446,XY,t(5;17)(q35;q12),i(21)(q10)Presented with cutaneous mastocytosis and leukemia cutis at the age of 6 months with spontaneous regression within 6 month; followed by leukemia development at 4 years; remission to ATRA.
7.M/5246,XY,t(5;17)(q35;q12)Preceded by myeloid sarcoma; induction therapy including ATRA resulted in complete hematological and molecular remission.

Abbreviations: M, male; F, female; ATRA; all-trans-retinoic acid.
1. Corey et al., 1994 and Redner et al., 1996. 2. Hummel et al., 1999; 3. Grimwade et al., 2000; 4. Xu et al., 2001; 5. Nicci et al., 2005; 6. Otsubo et al., 2012; Kikuma et al., 2015.
Cytology Hypergranular and hypogranular bilobed promyelocytes; absence of Auer rods; typical microspeckeled pattern with anti-RARa antibodies; terminal differentiation of blasts and promyelocytes in vitro with ATRA.
Prognosis The 2.5 years-old child (Corey et al., 1994; Redner et al., 1996) was treated with ATRA while in partial remission and relapsed shortly after ATRA cessation. One of the 12-years old males (Hummel et al., 1999) received chemotherapy in induction and consolidation and relapsed after 5 months; remission was obtained with Ara-C and ATRA therapy followed by allogenic BM transplantation, but relapsed with therapy refractoriness. The second 12-years old male who presented with severe DIC died of cerebral hemorrhage after 5 days of ATRA treatment (Xu et al., 2001). The 9-year-old female was treated with ATRA as a part of induction therapy and was alive in first CR at 29 months (Grimwade et al 2000). The last pediatric patient presented with aleukemic leukemia cutis and t(5;17)(q35;q12) NPM1/RARA fusion at the age of 6-month-old (Kanegane et al., 2009; Otsubo et al., 2012). He showed no sign of leukemia without any therapy after 12 months, except for the presence of NPM1-RARA transcript in the bone marrow, but developed APL at the age of 4 years with complete remission to ATRA. Both adult patients received ATRA as part of induction therapy, resulting in cytogenetic but not a molecular remission in 1 patient who relapsed at 22 months after diagnosis (Nicci et al., 2005), and in complete hematological and molecular remission in the other case (Kikuma et al., 2015).
From these data, the response to ATRA is difficult to assess since it was not part of induction treatment in some cases and due to the limited number of patients. However, patients with NPM1/RARA fusion appear to be sensitive to ATRA (Hummel et al., 1999; Grimwade et al., 2000; Kikuma et al., 2015) and cells bearing the t(5;17) terminally differentiate in its response (Redner et al., 1996), indicating that ATRA can be used to treat NPM1/RARA-positive APL patients. It is also possible that the presence of the additional/complex karyotypic abnormalities may be related to the prognosis in this group of patients.

Cytogenetics

Additional anomalies Sole anomaly in both adult patients (Nicci et al., 2005; Kikuma et al., 2015) and associated with additional anomalies in pediatric patients: del(12p) in 1 (Xu et al., 2001), i(21)(q10) in 1 (Otsubo et al., 2012) and complex anomalies in 2 cases (Hummel et al., 1999; Grimwade et al., 2000).
Variants Variant chromosome translocations, which fuse RARA with 1 of the partner genes: PML (promyelocytic leukemia protein) in t(15;17)(q22;q21) that is found in the majority of APL patients; ZBTB16 (zinc finger and BTB domain containing 16, previously known as PLZF) in t(11;17)(q23;q21) (De Braekeleer et al., 2014); NUMA1 (nuclear matrix-mitotic apparatus protein 1 gene) in t(11;17)(q13;q21) (Wells et al., 1997); STAT5B (signal transducer and activator of transcription 5 beta) in dup(17)(q21.3q23) (Chen et al., 2012); PRKAR1A (protein kinase, cAMP-dependent, regulatory, type I, alpha) in t(17;17)(q21;q24)/del(17)(q21q24) (Catalano et al., 2007); FIP1L1 (factor interacting with PAP 1-like 1) in t(4;17)(q12;q21) (Buijs et al., 2007); NABP1 (OBFC2A: oligonucleotide/oligosaccharide-binding fold containing 2A) in der(2)t(2;17)(q32;q21) (Won et al., 2013); TBL1XR1 (TBLR1, GenBank KF589333) in a complex t(3;17)(q26;q21), t(7;17)(q11.2;q21) (Chen et al., 2014); BCOR (BCL6 corepressor gene) in t(X;17)(p11.4;q21) (Ichikawa et l., 2015) and the recently described new RARA partner IRF2BP2 (interferon regulatory factor 2 binding protein 2) in t(1;17)(q42.3; q21) (Yin et al., 2015).

Genes involved and Proteins

Gene Name NPM1
Location 5q35
Protein Gene for the nucleolar phosphoprotein nucleophosmin; would participate in ribosome assembly.
Gene Name RARA
Location 17 q21
Protein Gene for the retinoic acid receptor alpha. Ligand-dependent transcription factor specifically involved in hematopoietic cells differentiation and maturation. Receptor for all-trans retinoic acid (ATRA) and 9-cis RA. After linking with ATRA, RARA binds with RXR (retinoid X receptor protein) to the RARE domain (retinoic acid response elements), a DNA sequence common to a number of genes. The breakpoint lies within the second intron of the gene, as in t(15;17) and t(11;17) translocations.

Result of the chromosomal anomaly

Hybrid gene
Description Two reciprocal fusion genes are generated: 5'-NPM1 + 3'- RARA on der(5) and 5'-RARa + 3'-NPM on der(17); both fusion genes are transcribed, the crucial one is NPM1/RARA; two NPM1/RARA chimeric cDNAs are generated, one short and one long differing from 129 bp, with corresponding transcripts of 2.3 and 2.4 kb (alternatively spliced transcripts); in one case, only the short NPM1/RARA isoform could be detected; the 5' end of NPM1/RARA cDNAs contains the first 442 bp of the NPM1 cDNA; the 3' end contains RARA sequences of exon 3 through the 3' end of RARA; a reciprocal RARA/NPM1 transcript is detected: RARA exons 1 and 2 are fused to 3' NPM1 downstream bp 443.
Detection Nested RT-PCR.
  
Fusion Protein
Description Two NPM1/RARA proteins, of 563 and 520 amino acids, are encoded (MW 62 and 57 kDa); NPM1/RARA fusion protein acts as a retinoic acid-responsive transcriptional activator: increase of activity in a concentration dependant manner.
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

Variant and masked translocations in acute promyelocytic leukemia.
Brunel V, Lafage-Pochitaloff M, Alcalay M, Pelicci PG, Birg F
Leukemia & lymphoma. 1996 ; 22 (3-4) : 221-228.
PMID 8819070
 
Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia.
Buijs A, Bruin M.
Leukemia 2007 May;21(5):1104-8.
PMID 17301809
 
Acute promyelocytic leukemia with a STAT5b-RAR? fusion transcript defined by array-CGH, FISH, and RT-PCR.
Chen H, Pan J, Yao L, Wu L, Zhu J, Wang W, Liu C, Han Q, Du G, Cen J, Xue Y, Wu D, Sun M, Chen S.
Cancer Genet 2012 Jun;205(6):327-31.
PMID 22749039
 
TBLR1 fuses to retinoid acid receptor ? in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, Xing H, Tian Z, Tang K, Mi Y, Wang B, Wang M, Wang J.
Blood 2014 Aug 7;124(6):936-45.
PMID 24782508
 
Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL, Xiong SM, Zhu J, Guo WM, Chen JQ, Xu SF, So E, Chan LC, Waxman S, Zelent A, Chen GQ, Dong S, Liu JX, Chen SJ
Proceedings of the National Academy of Sciences of the United States of America. 1999 ; 96 (11) : 6318-6323.
PMID 10339585
 
A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features.
Corey SJ, Locker J, Oliveri DR, Shekhter-Levin S, Redner RL, Penchansky L, Gollin SM
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1994 ; 8 (8) : 1350-1353.
PMID 8057672
 
RARA fusion genes in acute promyelocytic leukemia: a review.
De Braekeleer E, Douet-Guilbert N, De Braekeleer M.
Expert Rev Hematol 2014 Jun;7(3):347-57.
PMID 24720386
 
The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.
Grimwade D
British journal of haematology. 1999 ; 106 (3) : 591-613.
PMID 10468848
 
Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia.
Hummel JL, Wells RA, Dubé ID, Licht JD, Kamel-Reid S
Oncogene. 1999 ; 18 (3) : 633-641.
PMID 9989813
 
Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene.
Ichikawa S, Ichikawa S, Ishikawa I, Takahashi T, Fujiwara T, Harigae H.
Cancer Genet 2015 Apr;208(4):162-3.
PMID 25790901
 
Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastocytosis.
Kanegane H, Nomura K, Abe A, Makino T, Ishizawa S, Shimizu T, Naoe T, Miyawaki T.
Int J Hematol 2009 Jan;89(1):86-90.
PMID 19052694
 
A new transcriptional variant and small azurophilic granules in an acute promyelocytic leukemia case with NPM1/RARA fusion gene.
Kikuma T, Nakamachi Y, Noguchi Y, Okazaki Y, Shimomura D, Yakushijin K, Yamamoto K, Matsuoka H, Minami H, Itoh T, Kawano S.
Int J Hematol 2015 Dec;102(6):713-8.
PMID 26342691
 
Acute promyelocytic leukemia following aleukemic leukemia cutis harboring NPM/RARA fusion gene.
Otsubo K, Horie S, Nomura K, Miyawaki T, Abe A, Kanegane H.
Pediatr Blood Cancer 2012 Nov;59(5):959-60.
PMID 22573339
 
PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia.
Pandolfi PP
Haematologica. 1996 ; 81 (5) : 472-482.
PMID 8952164
 
Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid.
Redner RL, Corey SJ, Rush EA
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 (7) : 1014-1016.
PMID 9204984
 
The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.
Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ
Blood. 1996 ; 87 (3) : 882-886.
PMID 8562957
 
OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia.
Won D, Shin SY, Park CJ, Jang S, Chi HS, Lee KH, Lee JO, Seo EJ.
Blood 2013 Feb 21;121(8):1432-5.
PMID 23287866
 
Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.
Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE.
J Natl Compr Canc Netw 2015 Jan;13(1):19-22.
PMID 25583766
 

Citation

This paper should be referenced as such :
Zamecnikova A, al Bahar S
t(5;17)(q35;q21) NPM1/RARA;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/t517ID1081.html
History of this paper:
Viguié, F. t(5;17)(q35;q21). Atlas Genet Cytogenet Oncol Haematol. 2000;4(2):72-73.
http://documents.irevues.inist.fr/bitstream/handle/2042/37618/03-2000-t517ID1081.pdf


Other genes implicated (Data extracted from papers in the Atlas) [ 2 ]

Genes NPM1 RARA

Translocations implicated (Data extracted from papers in the Atlas)

 t(5;17)(q35;q21) NPM1/RARA

External links

NPM1 (5q35.1) RARA (17q21.2)

NPM1 (5q35.1) RARA (17q21.2)

Mitelman databaset(5;17)(q35;q21) [Case List]    t(5;17)(q35;q21) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
Mitelman databaseNPM1/RARA [MCList]  NPM1 (5q35.1) RARA (17q21.2)
TICdbNPM1/RARA  NPM1 (5q35.1) RARA (17q21.2)
 
Disease databaset(5;17)(q35;q21) NPM1/RARA
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 30 11:23:59 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.